MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-10-2023
Country |
 USA |
IPO year |
2016 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
36.5 M |
Market Cap[1] |
$ 6.29 B |
EBITDA (LTM) |
$ 1.14 M |
P/E (LTM) |
- |
P/S (LTM) |
2610.63 |
EPS (LTM) |
-9.35 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Veracyte
VCYT
|
$ 30.92 | -5.73 % | $ 2.43 B | Nasdaq Global Market,SPB | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market |  Israel |
 |
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Avid Bioservices
CDMO
|
- | - | $ 789 M | Nasdaq Capital Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 12.67 | -9.24 % | $ 1.92 B | Nasdaq Global Select Market,SPB | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 321.51 | -2.03 % | $ 42.1 B | Nasdaq Global Select Market,SPB | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | USA |
 |
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.09 | - | $ 22.4 M | Nasdaq Capital Market | Israel |
 |
Enochian Biosciences
ENOB
|
- | - | $ 40.5 M | Nasdaq Capital Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Equillium
EQ
|
$ 1.91 | -7.28 % | $ 109 M | Nasdaq Global Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 19.46 | -0.36 % | $ 910 M | Nasdaq Global Select Market | USA |
 |
Amarin Corporation plc
AMRN
|
$ 14.23 | -2.97 % | $ 5.91 B | Nasdaq Global Market |  Irlanda |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 45.99 | -3.28 % | $ 4.14 B | Nasdaq Global Market,SPB |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.33 | -2.81 % | $ 830 M | Nasdaq Global Select Market | Canada |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
- | - | $ 384 M | Nasdaq Global Select Market | Britain |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.